Allergan's eyelash drug may expand options for some patients
The recent announcement by Allergan that its new eyelash-enhancing drug is moving toward approval has plastic surgeons looking forward to a cosmetic enhancement that some say will be quite popular with patients and could provide a nice boost to plastic surgery practices.
Allergan, based in Irvine, CA, recently announced that it intends to file a new drug application by the end of the third quarter of this year with the FDA for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.
Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in -significant eyelash growth, says Scott Whitcup, MD, executive vice president of research and development at Allergan.
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- FDA hopes hospitals will switch to newly regulated pharmacies
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- The 5 Biggest Healthcare Finance Trouble Spots
- The Most Polarizing Topics in Healthcare IT
- New G-Code to Pay Doctors for Broad Array of Non-Face-to-Face Care
- Why You Should Involve Patients in Nursing Handoffs
- How CPOE Will Make Healthcare Smarter
- States Rejecting Medicaid Expansion Forgo Billions in Federal Funds
- Nonprofit Hospital Outlook 'Negative' in 2014